These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 32047478

  • 1. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 3. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 4. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Jun 29; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 5. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
    Zhang Z, Sharma R, Hamad L, Riebandt G, Attwood K.
    Diabetes Res Clin Pract; 2023 Aug 29; 202():110776. PubMed ID: 37311494
    [Abstract] [Full Text] [Related]

  • 6. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X, Yang M, Wang L, Li L, Zhong X.
    Medicine (Baltimore); 2021 May 14; 100(19):e25795. PubMed ID: 34106616
    [Abstract] [Full Text] [Related]

  • 7. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.
    Eur J Endocrinol; 2019 Sep 14; 181(3):363-374. PubMed ID: 31330498
    [Abstract] [Full Text] [Related]

  • 8. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
    Maamari J, Yeung SJ, Chaftari PS.
    Am J Emerg Med; 2019 Feb 14; 37(2):376.e1-376.e2. PubMed ID: 30361152
    [Abstract] [Full Text] [Related]

  • 9. Pembrolizumab-induced type 1 diabetes.
    Maia A, Soares DM, Azevedo S, Pereira T, Amaral C.
    J Oncol Pharm Pract; 2024 Sep 14; 30(6):1118-1121. PubMed ID: 38766907
    [Abstract] [Full Text] [Related]

  • 10. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P, Liu S, Cao H.
    J Med Case Rep; 2024 Jan 22; 18(1):51. PubMed ID: 38247005
    [Abstract] [Full Text] [Related]

  • 11. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 22; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 12. Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM.
    Zhang W, Chen J, Bi J, Ding N, Chen X, Wang Z, Jiao Y.
    Front Endocrinol (Lausanne); 2022 Nov 22; 13():1084441. PubMed ID: 36686495
    [Abstract] [Full Text] [Related]

  • 13. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
    Ishi A, Tanaka I, Iwama S, Sakakibara T, Mastui T, Kobayashi T, Hase T, Morise M, Sato M, Arima H, Hashimoto N.
    Endocr J; 2021 May 28; 68(5):613-620. PubMed ID: 33790087
    [Abstract] [Full Text] [Related]

  • 14. Anti-PD-1 Therapy-Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma.
    Samoa RA, Lee HS, Kil SH, Roep BO.
    Diabetes Care; 2020 Sep 28; 43(9):2293-2295. PubMed ID: 32616607
    [Abstract] [Full Text] [Related]

  • 15. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 16. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR, Schumacher CA, Harpe SE.
    Pharmacotherapy; 2017 Feb 19; 37(2):187-194. PubMed ID: 27931088
    [Abstract] [Full Text] [Related]

  • 17. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
    Zand Irani A, Almuwais A, Gibbons H.
    BMJ Case Rep; 2022 Jan 17; 15(1):. PubMed ID: 35039353
    [Abstract] [Full Text] [Related]

  • 18. Fulminant diabetes due to immune checkpoint inhibitors in the emergency department.
    Peyrony O, Ellouze S, Fontaine JP, Mohamadou I, Zafrani L.
    Am J Emerg Med; 2020 Feb 17; 38(2):408.e3-408.e4. PubMed ID: 31759780
    [Abstract] [Full Text] [Related]

  • 19. Diabetic ketoacidosis following immunotherapy for lung cancer.
    Skorpen PK, Margull J.
    Tidsskr Nor Laegeforen; 2019 Feb 26; 139(4):. PubMed ID: 30808100
    [No Abstract] [Full Text] [Related]

  • 20. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.